LEADER 04183nam 2200577 a 450 001 9910967544703321 005 20251116181713.0 010 $a1-61324-739-7 035 $a(CKB)2550000001042175 035 $a(EBL)3019568 035 $a(SSID)ssj0000852593 035 $a(PQKBManifestationID)12368641 035 $a(PQKBTitleCode)TC0000852593 035 $a(PQKBWorkID)10853103 035 $a(PQKB)10790637 035 $a(MiAaPQ)EBC3019568 035 $a(Au-PeEL)EBL3019568 035 $a(CaPaEBR)ebr10671133 035 $a(OCoLC)830627793 035 $a(BIP)32691832 035 $a(EXLCZ)992550000001042175 100 $a20101014d2011 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aE. coli infections $ecauses, treatment and prevention /$fMorgan C. Rogers and Nancy D. Peterson, editors 205 $a1st ed. 210 $aHauppauge, N.Y. $cNova Science Publishers Inc.$d2011 215 $a1 online resource (270 p.) 225 1 $aBacteriology research developments 300 $aDescription based upon print version of record. 311 08$a1-61122-859-X 320 $aIncludes bibliographical references and index. 327 $aUropathogenic escherichia coli : the pre-eminent urinary tract infection pathogen / David W. Hilbert, Women's Health Research Center, Medical Diagnostic Laboratories, Hamilton, New Jersey, USA -- E. coli Infections in Urology : Causes, Treatment and Prevention / Chelsea N. Elwood, Peter Cadieux, Dirk Lange, The Stone Centre at Vancouver General Hospital, University of British Columbia (UBC), Vancouver, British Columbia, Canada, and others -- Aptamer-Based Detection and Therapeutics to Prevent and Treat E. coli Infections / John G. Bruno, Maria P. Carrillo, Taylor Phillips, Alissa Savage, Joseph R. Koke, Operational Technologies Corporation, San Antonio, Texas, USA, and others -- Lactoferrin : A Novel Natural Host Defense Protein against Escherichia coli Infection / Chih-Ching Yen, Hsiao-Ling Chen, Chuan-Mu Chen, Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan, and others -- 327 $aPerinatal Antibiotic Use and Antimicrobial Resistance : Examining Escherichia coli as a Model / Nevio Cimolai, Program of Microbiology, Virology, and Infection Control, Children's and Women's Health Centre of British Columbia, Vancouver, British Columbia, Canada, and others -- Implication of Enterotoxigenic Escherichia coli Pathogenicity from the Human Perspective / Iram Liaqat, University of Western Australia -- Prevention of E. coli Infections using Organic Acids / Eva Skrivanova?, Milan Marounek, Institute of Animal Science, Department of Physiology of Nutrition and Quality of Animal Products, Pra?telstvi?, Prague, Czech Republic -- Current Status on the Etiology, Epidemiology, Food Safety Implications and Control Measures in Escherichia coli 0157:H7 Infections / G. Normanno, Department of Health and Animal Welfare, Faculty of Veterinary Medicine, Valenzano (Ba), Italy -- Maillard Reaction and Spontaneous Mutagenesis in Escherichia coli / Roumyana Mironova, Yordan Handzhiyski, Toshimitsu Niwa, Alfredo Berzal-Herranz, Kirill A. Datsenko, Barry L. Wanner, Ivan Ivanov, Department of Gene Regulations, Institute of Molecular Biology, Bulgarian Academy of Sciences, Sofia, Bulgaria, and others. 330 $aPresents research in the study of E coli infections, including urinary tract infections caused by E coli; aptamer-based detection and therapeutics to prevent and treat E coli infections; Lactoferrin as a novel natural host defence protein; enterotoxigenic escherichia coli colonisation factors; and, the prevention of E coli using organic acids. 410 0$aBacteriology research developments series. 606 $aEscherichia coli infections 615 0$aEscherichia coli infections. 676 $a579.3/42 701 $aRogers$b Morgan C$01863498 701 $aPeterson$b Nancy D$01863499 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910967544703321 996 $aE. coli infections$94470148 997 $aUNINA